Watson Pharmaceuticals (NYSE:WPI) faces a delay in the approval of a vaginal gel that addresses high-risk pregnancies because it received a complete response letter from U.S. regulators. The letter from the U.S. Food and Drug Administration said the results of phase 3 clinical trial for progesterone vaginal gel 8% did not meet the level of […]
Watson Pharmaceuticals (NYSE:WPI) wants to add a branded drugs focus alongside its generics business and is setting aside $6 billion for acquisitions to do it, according to a report by Bloomberg. Chief executive officer Paul Bisaro said: “Everything we need to be a branded pharma company we have, except for the sales force. … And […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Watson Pharmaceuticals (NYSE:WPI) has said it will build a $4.5 million research and development facility focused on developing respiratory products and inhalation technology in New Jersey. The drugmaker does not currently have a respiratory or inhalation platform, “so we will be establishing that organically,” a spokeswoman for the company said. About 50 new and current […]
A U.S. Food and Drug Administration panel has voted against Columbia Laboratories‘ (Nasdaq: CBRX) and Watson Pharmaceuticals’ (NYSE: WPI) progesterone vaginal gel 8% to reduce preterm birth in women, saying the panel requires more information. The Advisory Committee for Reproductive Health Drugs said the gel did not produce a statistically significant reduction in preterm births […]